Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus ZEGERID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus ZEGERID.
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM vs ZEGERID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
20 mg or 40 mg orally once daily before a meal.
None Documented
None Documented
Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation).
1.0–1.5 hours in plasma; however, the pharmacodynamic half-life is longer due to irreversible inhibition of H+/K+-ATPase; drug effect persists for 24 hours after single dose.
Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal.
Approximately 82% renal (as metabolites), 18% fecal (via bile); less than 1% unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor